Modality
ASO
MOA
KRASG12Di
Target
AHR
Pathway
Lipid Met
ALSGastric Ca
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
~Jan 2019
→ ~Apr 2020
Phase 2
Jul 2020
→ Aug 2030
Phase 2Current
NCT03663918
2,331 pts·Gastric Ca
2023-07→TBD·Recruiting
NCT07249712
654 pts·ALS
2020-07→2030-08·Completed
2,985 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-08-164.4y awayPh2 Data· ALS
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Complet…
P2
Recruit…
Catalysts
Ph2 Data
2030-08-16 · 4.4y away
ALS
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03663918 | Phase 2 | Gastric Ca | Recruiting | 2331 | MRD |
| NCT07249712 | Phase 2 | ALS | Completed | 654 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Doxalemzoparlimab | Nuvalent | Approved | AHR | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα |